Disease
|
Diagnostic
/ Follow-up
|
Target
|
Comment
|
ACUTE
LEUKEMIA
|
Diagnostic & Follow-up
|
Activating
mutation (Internal tandem duplication) of the FLT3 |
Responsiveness
to Various FLT3 Inhibitors
|
ACUTE
LEUKEMIA
|
Diagnostic & Follow-up
|
Activating
mutations in exon 14 of the FLT3 |
Responsiveness
to Various FLT3 Inhibitors
|
| ACUTE
MYELOID LEUKEMIA |
Diagnostic & Follow-up |
Mutations
in Exons 8, 11 AND 17 in KIT |
Gleevec/Imatinib
Responsiveness |
ACUTE
MYELOID LEUKEMIA
|
Follow-up |
Exon
20 Mutations in FLT3 (Including ASP835)
|
Responsiveness
to Various FLT3 Inhibitors |
BONE
MARROW TRANSPLANT: ENGRAFTMENT CONTROL
|
Follow-up
|
STR
Markers
|
Chimerism
|
CHRONIC
MYELOID LEUKEMIA AND ACUTE LEUKEMIA
|
Diagnostic & Follow-up
|
Mutations
in Exons 4-10 of the ABL Gene (Including T315I)
|
Gleevec/Imatinib
Responsiveness
|
CHRONIC
MYELOMONOCYTIC LEUKEMIA (CMML)
|
Diagnostic |
V617F
Mutation in JAK2 |
|
| ESSENTIAL
THROMBOCYTHEMIA |
Diagnostic |
V617F
Mutation in JAK2 |
|
HYPEREOSINOPHILIC
SYNDROME
|
Diagnostic |
V617F
Mutation in JAK2 |
|
MAST
CELL LEUKEMIA
|
Diagnostic & Follow-up |
Mutations
in Exon 17 in KIT
|
Gleevec/Imatinib
Responsiveness |
| MASTOCYTOSIS |
Diagnostic & Follow-up |
Mutations
in Exon 17 in KIT
|
Gleevec/Imatinib
Responsiveness |
MYELOID
METAPLASIA WITH MYELOFIBROSIS
|
Diagnostic |
V617F
Mutation in JAK2 |
|
NEUTROPHILIC
LEUKEMIA (CNL)
|
Diagnostic |
V617F
Mutation in JAK2 |
|
POLYCYTHEMIA
VERA
|
Diagnostic |
V617F
Mutation in JAK2
|
|
SYSTEMIC
MASTOCYTOSIS
|
Diagnostic |
V617F
Mutation in JAK2 |
|
THE
MYELODYSPLASTIC SYNDROMES
|
Diagnostic |
V617F
Mutation in JAK2 |
|